



Innovative ocular solutions: Improving lives through advanced therapies

A legacy of excellence, a vision for change

With a proud 30-year heritage as a leading CRO, Fortrea combines the rich legacy of Covance and Labcorp Drug Development with the specialized ophthalmology expertise gained from Chiltern, in the 2017 acquisition. Our extensive experience spans multiple indications, from front and back-of-the-eye conditions to rare ocular diseases, cell and gene therapies, pediatrics and ophthalmic devices and diagnostics.

At Fortrea, we are dedicated to collaborating with pharma and biotech clients to design trials that minimize the burden on all stakeholders—especially patients, caregivers and sites, whilst prioritizing patient safety and delivering high-quality data. In the past five years alone, we've collaborated on over **131 ophthalmology trials across 55 countries**, showcasing our commitment to advancing global ocular therapies.

KEY TAKEAWAYS

131*

Patient-centric ophthalmology clinical trials with **3,989 sites** and **28,452 patients** (72% posterior/28% anterior split)

30*

Ocular cell and gene therapy studies; executed across **11** countries

38*

Rare ocular disease trials

* 5-year data from 2020 Q3 - 2025 Q3


Extending your team's expertise through collaboration and strategic vision

At Fortrea, we strive to be more than just a CRO; we take a one-team approach with our clients, sites, patients and third-party vendors.

- **CRO of choice:** We strive to be the CRO of choice for our clients and sites; through our nimble, flexible approach that larger, less specialized CROs often can't match. Your success is our sole focus—we'll build on our commitment to best-in-class service, celebrating and promoting a culture of transparent and exceptional collaboration
- **Leveraging insight-driven experience to unlock success:** We have deep scientific and regulatory experience; insights that help provide flexible solutions for both large pharma and emerging and mid-size biotech companies
- **Agility at scale:** You can rely on us to extend your team with the global scalability to deliver everything from first-in-human to Phase III ophthalmology studies, to post marketing commitments. Driven to deliver by a culture of creative problem solving, agile thinking and excellence in delivery

We provide comprehensive support for clinical trials, including consultation, customized study monitoring, protocol writing, global logistics, specimen management, lab management and oversight, patient and site support services, regulatory support and ocular-specific vendor contracting and management. Our delivery capabilities are designed to match your preferences and the needs of your project and include comprehensive full-service, functional service provider (FSP) solutions and consulting services.

Top indications in Fortrea ophthalmology studies 2020 Q3 - 2025 Q2



Enhancing your drug development journey with tailored solutions

Enhancing your drug development journey with tailored solutions, Fortrea leverages multiple differentiated site relationships, data sources and vendors to establish a realistic and deliverable strategy.

Site relationships: We're leading the way in transforming the landscape of clinical research by listening, collaborating and responding to the needs of sites, leaving them free to do what sites do best; delivering care to patients.

Vendors: Fortrea has established relationships and experience with ophthalmic central reading and visual acuity vendors who are critical to delivering primary endpoints and drive study success with quality.

Data sources: Fortrea was the first CRO to partner with **Verana Health**, recognizing the value that real-world data from the American Academy of Ophthalmology's IRIS[®] Registry ([Intelligent Research in Sight—www.aao.org/iris-registry](http://www.aao.org/iris-registry)) brings to developing a strategy for our clients. Through Verana Health's exclusive collaboration with the Academy, Fortrea has near real-time

access to a set of curated, de-identified data and practice-level insights from the IRIS Registry to inform protocol design, enhance site selection and support patient recruitment strategies.

The explosion of technology "solutions" required for trials is hindering rather than helping sites. We're changing that. By leveraging our unique vantage point in the industry, we're layering our experience over the technology and data offerings from best-in-class providers to dramatically simplify the experience for patients, sites and clients.

Our collaborator sites recruit patients **1.8 times faster** on average than non-collaborator sites and achieve approximately **17% faster start-up timelines**

Optimizing clinical trials and patient-centric solutions on the path to commercialization

At Fortrea, we are driven to deliver with urgency and flexibility. Our extensive experience with regulatory and commercial guidance, in assisting both small biotech and large pharma companies, promotes goal achievement. Collaborate with us to ensure your ophthalmology product meets regulatory, provider, payer, policymaker and patient expectations—optimizing your commercial opportunities.

Product development: Accelerate your ocular product to market with our experienced consulting services and benefit from a holistic approach, reducing your burden as we combine cross-functional ophthalmology experience across all phases of our development program.

- **Clinical pharmacology services:** Provides the link between preclinical data and new treatments for patients. Phase I units equipped with the ocular equipment you need to make rapid “go/no go” decisions
- **Regulatory strategy:** Let our strategists with ophthalmology experience help you navigate regulatory processes (agency meetings, IND development and filing) and programs. Additionally, to keep your ocular asset moving forward, we can support with timeline development alongside your nonclinical, CMC and clinical requirements

Market Access & Health Economics and Outcomes Research (HEOR): You need clarity on your product’s value early to optimize access and enable commercial success. Our services include endpoint strategy, research and implementations and evidence generation.

Fortrea has the experience and understanding of how to operationalize ophthalmology studies and all the related nuances, focusing on reducing site and patient burden.



Our mission is clear: To be your CRO of choice

LEARN MORE at fortrea.com